Background: Postmortem and positron emission tomography (PET) studies have reported several alterations in serotonin 1A receptor (5-HT(1A)) binding parameters in patients with schizophrenia. This study examines 5-HT(1A) availability in vivo in individuals with schizophrenia and schizo-affective disorder.
Materials And Methods: Twenty-two medication-free individuals with schizophrenia or schizo-affective disorder and 18 healthy subjects underwent PET scans with [(11)C]WAY 100635. Regional distribution volumes (V(T), in milliliters per gram) were derived using a two-tissue compartment kinetic model. Outcome measures for 5-HT(1A) availability included binding potential (BP) and the specific to nonspecific equilibrium partition coefficient (V(3)''). Eleven brain regions with high density of 5-HT(1A) were included in the analysis.
Results: No significant differences were observed in regional BP or V(3)'' between patients and controls. No significant relationships were observed between regional 5-HT(1A) availability and symptom severity.
Conclusion: The postmortem literature reports increased 5-HT(1A) binding in the prefrontal cortex in schizophrenia. This study did not detect differences in 5-HT(1A) binding. Whereas in two recently published PET studies, one reports increased binding in the temporal lobe while the other reports decreased binding in the amygdala. These inconsistencies suggest that the alterations demonstrated in postmortem studies cannot be reliably detected at the resolution achieved with PET. This raises the question as to whether major changes in the level of expression of the 5-HT(1A) receptor play a role in the pathophysiology of schizophrenia.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00213-006-0543-8 | DOI Listing |
Psychiatry Res
September 2024
University of Kragujevac, Faculty of Medical Sciences, Department of Psychiatry, Liceja Knezevine Srbije 1A, Kragujevac 34000, Serbia.
Clozapine remains the only pharmacological treatment option for treatment-resistant schizophrenia. Therapeutic drug monitoring (TDM) of clozapine is recommended, although evidence for the therapeutic range of 350-600 ng/ml is limited. In various countries including Serbia, TDM of clozapine is not routinely performed.
View Article and Find Full Text PDFSchizophr Res
January 2024
Pôle de Psychiatrie, Santé Mentale et Addictologie, University Hospital Strasbourg, France; Physiopathologie et Psychopathologie Cognitive de la Schizophrénie - INSERM 1114, Strasbourg, France; University of Strasbourg, France; FMTS, Strasbourg, France; Fondation FondaMental, 94000 Créteil, France. Electronic address:
Catatonia has been defined by ICD-11 as a nosologically unspecific syndrome. Previous neuropsychiatric conceptions of catatonia such as Wernicke-Kleist-Leonhard's (WKL) one, have isolated chronic catatonic entities, such as progressive periodic catatonia (PPC) and chronic system catatonias (CSC). This study aimed at comparing the clinical and neuropsychological features of PPC, CSC and non-catatonic patients, all diagnosed with a schizophrenia spectrum disorder (SSD).
View Article and Find Full Text PDFCompr Psychiatry
November 2022
Semmelweis University, Faculty of Medicine, Department of Psychiatry and Psychotherapy, 1082 Balassa str 6, Budapest, Hungary.
Nat Commun
August 2022
Tri-institutional Center for Translational Research in Neuroimaging and Data Science (TReNDS), [Georgia State University, Georgia Institute of Technology, Emory University], Atlanta, GA, USA.
Schizophrenia is a highly heritable psychiatric disorder characterized by widespread functional and structural brain abnormalities. However, previous association studies between MRI and polygenic risk were mostly ROI-based single modality analyses, rather than identifying brain-based multimodal predictive biomarkers. Based on schizophrenia polygenic risk scores (PRS) from healthy white people within the UK Biobank dataset (N = 22,459), we discovered a robust PRS-associated brain pattern with smaller gray matter volume and decreased functional activation in frontotemporal cortex, which distinguished schizophrenia from controls with >83% accuracy, and predicted cognition and symptoms across 4 independent schizophrenia cohorts.
View Article and Find Full Text PDFNicotine Tob Res
March 2022
Hebrew University-Hadassah Braun School of Public Health & Community Medicine, Jerusalem, Israel.
Introduction: People with serious mental illness (SMI) are three times more likely to smoke and be heavy smokers than smokers without SMI. Counseling combined with smoking cessation medication (SCM) is the recommended treatment. However, until 2017, SCM prescription for SMI smokers was discouraged (FDA black box warning).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!